<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-one patients (median age = 34, range = 10-49; F:M = 7:14) received a preparative regimen consisting of <z:chebi fb="0" ids="28901">busulfan</z:chebi> 4 mg/kg/day x 4, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> 2 g/m2/12 h x 4 and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 60 mg/kg/day x 2 ('BAC' regimen) for allogeneic bone marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Out of 12 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), two were in first remission, six were in second remission and four had resistant, <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">relapsed disease</z:e> or prolonged marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> after induction chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Five of the 12 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> had <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Four patients had transfusion-dependent <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Three patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> were in the accelerated phase and two were in the <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Organ toxicities related to the preparative regimen were graded </plain></SENT>
<SENT sid="6" pm="."><plain>Liver toxicity occurred in 11 patients, two of these were fatal <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) (10%) </plain></SENT>
<SENT sid="7" pm="."><plain>Nineteen of the 21 patients had grade 2 or less <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and 13 also had mucositis </plain></SENT>
<SENT sid="8" pm="."><plain>One patient developed grade 3 cardiac toxicity, and one other patient had grade 1 skin toxicity </plain></SENT>
<SENT sid="9" pm="."><plain>Four patients had gross <z:hpo ids='HP_0000790'>hematuria</z:hpo> related to treatment (19%) </plain></SENT>
<SENT sid="10" pm="."><plain>No renal, pulmonary or <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> toxicities were encountered </plain></SENT>
<SENT sid="11" pm="."><plain>Ten patients have died, two from regimen-related hepatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Of the remaining eight <z:hpo ids='HP_0011420'>deaths</z:hpo>, four were from <z:hpo ids='HP_0002093'>respiratory failure</z:hpo> in four patients (one case each of Pneumocystis <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, CMV <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, <z:hpo ids='HP_0011946'>bronchiolitis obliterans</z:hpo> associated with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, and <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> complicated <z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">pulmonary emboli</z:e>), and one patient each from GI <z:mp ids='MP_0001914'>bleeding</z:mp>, <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo>, <z:hpo ids='HP_0100806'>sepsis</z:hpo> and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>Thus far, only one patient transplanted for <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> in second remission relapsed at day 230.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>